A Science & Innovation Webinar, presented by AbbVie Medical Affairs.

The objective of this Pharmacokinetic/Pharmacokinetic (PK/PD) analysis is to evaluate Bruton's Tyrosine Kinase (BTK) occupancy at doses included in the US Prescribing Information (USPI) dose modifications for adverse reactions recommendations.

• Review the dose modification guidance for adverse reactions included in the US Prescribing Information.
• Explain the PK/PD findings showing BTK occupancy at doses included in the USPI dose modifications for adverse reactions.

An AMCP CPE Webinar.

Federal drug pricing policy is moving rapidly from the Medicare Drug Price Negotiation Program (MFP) toward renewed interest in most-favored-nation (MFN)–style approaches, with ripple effects far beyond their stated intent. As price controls intersect with rebates, Medicaid best price, 340B, and growing price transparency, traditional pricing and formulary strategies are being tested in real time. Drawing on perspectives from policy, economics, Medicaid, employers, and formulary leaders, this session unpacks how these policies transmit through markets—and where theory breaks down in practice. Attendees will explore unintended consequences, including launch delays, benefit disruptions, rebate erosion, and shifting stakeholder trust. The discussion emphasizes practical implications for payers navigating affordability pressures, political uncertainty, and evolving pricing architectures. 

An AMCP Precision Medicine LINK Group Webinar.

Biomarker testing is central to delivering precision oncology, but adoption still varies by tumor type and care setting. Drawing on IQVIA's new Advancing Precision Oncology report, we will walk through current testing trends and the levers — clinical evidence, guideline inclusion, and institutional champions — that move biomarkers from evidence into everyday practice, along with the barriers still holding adoption back. We'll close with a quick pipeline update on what's next in oncology therapeutics.

Join us as AMCP Market Insights shares exclusive findings from our recent multi-stakeholder expert roundtable on treatment-resistant depression. This webinar will break down payer perspectives on clinical data, address the looming provider network shortage, and outline actionable strategies to prepare your behavioral health network for these emerging interventional treatments. Attendees will walk away with concrete recommendations on removing care barriers, updating coverage frameworks, and driving cross-industry collaboration to evaluate, cover, and operationalize these therapies safely and effectively.

The intersection of population health and managed care pharmacy becomes clearer when viewed through real-world application. Building from foundational concepts introduced in the first webinar, this session explores how population health principles are implemented across diverse settings, including employer groups, health plans, research organizations, and healthcare systems. Through case studies and practical examples, speakers will demonstrate how professionals with different roles and titles contribute to shared goals of improving health outcomes, enhancing patient experiences, and optimizing healthcare resources. Attendees will gain insight into how population health strategies are translated into action and discover opportunities to apply similar approaches within their own organizations.